Vanderbilt researchers will discuss their groundbreaking studies on Alzheimer’s disease and dementia at an upcoming forum, and the public is invited to attend.

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

Vanderbilt researchers have established a new measure of resilience to cognitive impairment in people with asymptomatic Alzheimer’s disease.

People with Alzheimer’s disease don’t perceive pain as readily as healthy older adults, and this may lead to delays and underreporting of pain. This alteration in pain detection may be one reason that people with Alzheimer’s disease and pain tend to be undermedicated and suffer unnecessarily, a trans-institutional group of Vanderbilt researchers reported recently in BMC Medicine.

A genetic risk factor for Alzheimer’s disease in later life appears to benefit younger adults as they age.

Vanderbilt University Medical Center has received a $9.4 million grant from the National Institute on Aging (NIA) to test the effectiveness of a transdermal nicotine patch in improving memory loss in older adults with mild cognitive impairment (MCI), a precursor to Alzheimer’s disease.

Vanderbilt University School of Nursing (VUSN) has been awarded a four-year $660,633 grant from the National Institute of Health’s National Institute on Aging to study how psychophysical responses to acute experimental thermal pain differ between older adults with and without Alzheimer’s Disease (AD).